Vikas Sinha

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.